



NORRIS
MEDICINES LIMITED



Factory : Plot No. 801/P, GIDC Estate,
ANKLেশWAR 393 002. (Gujarat)
Regd. Office : Plot No. 801/P, GIDC Estate,
ANKLেশWAR 393 002. (Gujarat)
Telephone : (02646) 223462, 227530
Fax : (02646) 250128
E-mail : contact@norrispharma.com
Website : www.norrispharma.com
CIN : L34230GJ1999PLC086661

Date- 14.08.2024

To
Bombay Stock Exchange Limited
Department of Corporate Services
14th Floor, P. J. Tower
Dalal Street, Fort,
Mumbai – 400 001.

Sub: Outcome of the Board Meeting held on Wednesday, 14th August, 2024 pursuant to regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

Ref.: NORRIS MEDICINES LTD (Scrip Code No. 524414).

Dear Sir,

With reference to above captioned subject, we wish to inform you that, the meeting of the Board of Directors of the Company, Norris Medicines Limited held today, i.e., Wednesday, 14th August, 2024 at 4.00 P.M. considered and approved the following:

1. Considered and approved Un-audited Financial Results for the quarter ended 30th June, 2024 along with Limited Review Report thereof.
2. Considered and approved the appointment of HSPN & Associates LLP, Practicing Company Secretaries, Mumbai as Secretarial Auditors for the financial year 2024-25.
3. Considered and approved appointment of M/s. Dhiren Y Parikh & Co, Chartered as Internal Auditors of the Company for the financial year 2024-25.
4. Considered and approved the day, date, time and venue of 33rd Annual General Meeting of the Company.
5. Considered and approved the Notice of 33rd Annual General Meeting of the Company.
6. Considered and approved the Director's Report as on 31st March, 2024.
7. Considered and approved closure of Register of Members and Share Transfer Book.
8. Considered and approved cut-off date to record the entitlement of shareholders to cast the votes electronically.
9. Considered and approved appointment of Central Depository Services Limited (CDSL) as Depository for E-Voting facility at 33rd Annual General Meeting of the Company.



NORRIS
MEDICINES LIMITED



Factory : Plot No. 801/P, GIDC Estate,
ANKLASHWAR 393 002. (Gujarat)
Regd. Office : Plot No. 801/P, GIDC Estate,
ANKLASHWAR 393 002. (Gujarat)
Telephone : (02646) 223462, 227530
Fax : (02646) 250128
E-mail : contact@norrispharma.com
Website : www.norrispharma.com
CIN : L34230GJ1999PLC086661

10. Considered and approved the appointment of Scrutinizer for 33rd Annual General Meeting of the Company.

The meeting was concluded at 4:30 P.M.

You are requested to kindly take it on your records.

Thanking you,

Yours truly,

For **NORRIS MEDICINES LIMITED**

VIMAL Digitally signed
by VIMAL D SHAH
D SHAH Date: 2024.08.14
16:45:47 +05'30'

MR. VIMAL DHIRENDRA SHAH
DIRECTOR
DIN: 01506655

BAHEDIA & ASSOCIATES

CHARTERED ACCOUNTANTS



SF-68 & 69, Hexzone Arcade, Beside Jayaben Modi Hospital, Towards Valia Road,
GIDC Estate, ANKLESHWAR - 393 002. ☎ : (02646) 221708

CA. B. L. Bahedia

(B.Com., D.T.P., LL.B., FCA.)

Mobile No. : +91 98241 36264, 97252 20412

E-mail : bbahedia@yahoo.com/gmail.com

Web : www.bahediaassociates.icai.org.in

Ref. No. :

Date :

"Limited Review Report"

To,

Board of Directors of NORRIS MEDICINES LIMITED

We have reviewed the accompanying statement of unaudited financial results of NORRIS MEDICINES LIMITED, REGD. OFF 801/P, GIDC ESTATE, ANKLESHWAR-393002, for the period ended 30th June, 2024. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors in their meeting held on 14/08/2024. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2400 "Engagement to Review Financial Statements", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

FOR, BAHEDIA & ASSOCIATES
CHARTERED ACCOUNTANTS
(FRN-114421W)

T. Bahedia

(CA. B.L. BAHEDIA)

PROPRIETOR

(M.NO.048066)

UDIN: - 24048066BKADJJ4673

PLACE: ANKLESHWAR

DATE: 14/08/2024



NORRIS MEDICINES LIMITED

Regd Off: 801/P, GIDC Estate, Ankleshwar, 393002, Gujarat.

Phone: 02646-223462 Fax 02646 -250126.

email: contact@norrispharma.com. Website: www.norrispharma.com

CIN No. L24230GJ1990PLC086581

Rs. In Lakhs

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30.06.2024

Sl. No.	Particulars	Quarter Ended 30.06.2024 Unaudited	Quarter Ended 31.03.2024 Audited	Quarter Ended 30.06.2023 Unaudited	Previous accounting year ended Audited
1	(a) Revenue from Operations	72.49	148.76	94.64	563.56
	(b) Other Income	1.16	2.84	-	2.84
	Total Income From Operations (Net)	73.65	151.60	94.64	566.40
2	Expenses				
	a. Cost of Materials Consumed	55.09	61.76	113.08	315.93
	b. Changes in Inventories of Finished Goods, work in Progress and stock in	(37.83)	(39.67)	(76.84)	-50.04
	c. Employee Benefit Expenses	34.31	40.96	59.74	182.05
	d. Finance Costs	8.45	11.14	8.61	36.98
	e. Depreciation and Amortisation Expense	13.18	13.87	14.32	57.15
	f. Other expenditure	37.07	37.17	37.22	134.12
	Total Expenses	110.27	125.23	156.13	676.19
3	Profit/ Loss before Tax (1-2)	-36.62	26.37	-61.49	-109.79
4	Tax Expense				
	a: Current Tax	0	0.00	0	0.00
	b: Deferred Tax	0	8.89	0	8.89
5	Profit / Loss after Tax	-36.62	17.48	-61.49	-118.68
6	Other Comprehensive Income				
a.	(i) Items that will not be reclassified to profit and loss account	0.00	0.00	0.00	0.00
	(ii) Income Tax relating to items that will not be reclassified to profit and loss	0.00	0.00	0.00	0.00
b.	(i) Items that will be reclassified to profit and loss account	0.00	0.00	0.00	0.00
	(ii) Income Tax relating to items that will be reclassified to profit and loss account	0.00	0.00	0.00	0.00
7	Total Comprehensive Income for the period	-36.62	17.48	-61.49	-118.68
8	Paid-up equity share capital (Face Value of Rs. 10/- each)	992.58	992.58	992.58	992.58
9	- Basic and diluted	-0.37	0.18	-0.62	-1.20

Notes:

1) The above Unaudited Financial Results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on 14.08.2024. The above results have been subjected to Limited Review by the Statutory Auditors of the Company.

2) The Financial results of the Company have been prepared with Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015 and SEBI circular dated 05.07.2016.


3) The Company is having one segment only and therefore Segmental Reporting is not applicable.

4) There are no exceptional/ extraordinary items during the quarter ended 30.06.2024

5) Previous year/ period figures have been regrouped/ rearranged wherever necessary to make them comparable with current period figures.

For Norris Medicines Limited


Vimal D Shah
Director



Date: 14.08.2024.
Place: Ankleshwar